Press Room

News / Apr 12, 2021

Guy Villax wins EY Award “Entrepreneur of the Year”

EY Entrepreneur Of The Year is the world's most prestigious business award for entrepreneurs

Guy Villax Wins Entreperneur of the Year Award | Hovione

Guy Villax won the EY award "Entrepreneur of the Year" in Portugal and he will represent Portugal at the EY World "Entrepreneur of the Year", next June.

Upon receiving the award, Guy Villax stated that this is an important distinction for Hovione, above all it recognizes the team that built this company over the last 25 years, and he thanked and congratulated all Hovione Team Members for the success. Guy Villax also said that we are a company with 60+ years, with strong values, with innovation at its core, but to endure into the future it needs to be able to constantly re-invent itself: “A company that does not move forward, dies. You have to constantly look for opportunities, look for ways to stay ahead of the competition, and innovation is central to success”.
 
The EY Award "Entrepreneur Of The Year" was created in the USA in 1986 to recognize and encourage Entrepreneurs that are marked by creativity that invest themselves in a corporate project with vision and achieve success. In Portugal, the EY “Entrepreneur Of The Year” is in its 8th edition.

 

Votes are open for the election of EY World Entrepreneur Of The Year™ 2021:

Cast your vote here

 

 

 

 

 

Also in the Press Room

See All

Integrated approach simplifies development, reduces risk, and supports scalable manufacturing. Hovione and Industrial Design Consultancy Ltd.’s (IDC) lead single-use nasal dry powder device is now available for commercial partnerships. Hovione and IDC have completed the device design and established initial device manufacturing and supply capability, enabling pharmaceutical partners to leverage existing capsule filling infrastructure. This approach simplifies development, reduces cost and risk, and helps shorten timelines to the clinic and commercialization. “This milestone marks an important step in the evolution of our collaboration with IDC — from device innovation to a fully integrated intranasal drug delivery platform,” said Márcio Temtem, Ph.D., Vice President, Strategic Business Management, Hovione. “As the industry looks for faster, more reliable ways to bring complex therapies to patients, integration becomes critical. By bringing together nasal particle engineering science, formulation manufacturing and filling, and device technologies into a single offering, we enable a more seamless and predictable development journey, accelerating the path to market for intranasal therapies.” The nasal delivery device enables broad and targeted nasal deposition flexibility while delivering maximum usability and reliability. With a patented design and manufacturing process established, the platform is available for partnering with pharmaceutical companies on an exclusive basis as part of Hovione’s integrated offering for inhalation and nasal drug development and manufacturing. Additionally, IDC’s Managing Director, Stephen Knowles Ph.D., said the companies are now “well-advanced” with the development of a multi-use device to support an even wider range of therapies and patient needs. Read the full article at ContractPharma.com    

Press Clipping

Hovione, IDC Launch Intranasal Drug Delivery Platform

May 07, 2026